Heres whats coming soon, and whats in clinical trials: Orforglipron (brand name Foundayo): A once-daily oral GLP-1 was just approved by the FDA for weight loss, and will hopefully be approved for type 2 diabetes soon
Symptoms may include facial or throat swelling, difficulty breathing or swallowing, itching or rash, fainting or feeling dizzy, or rapid heartbeat
US Health Secretary Robert F
The terms of the settlement are confidential and it remains unclear whether generic entry will happen once the main compound patent expires or later due the follow-on patents
These medications work directly on regions of the brain involved in appetite control, such as the hypothalamus, helping you feel fuller longer, reducing hunger sensations, and curbing cravings
The cardiovascular safety profile makes GLP-1 medications particularly attractive for people with diabetes who also have heart disease risk factors